StockIceMan's Weekly Stock Pick
Week of July
14th, 2003
| Stock: |
Pharmacyclics,
Inc. |
| |
|
| Ticker Symbol: |
PCYC - Nasdaq -
Biotechnology |
| |
|
| Buy: |
4.50 to 4.75 |
| |
|
| Sell: |
7.00 + |
| |
|
| Info: |
Pharmacyclics,
Inc. is a pharmaceutical company
developing products to improve
upon therapeutic approaches to
the treatment of cancer and
atherosclerosis. The Company uses
its expertise in the chemistry of
porphyrin-like biomolecules to
develop patented compounds called
texaphyrins. Texaphyrins are a
class of molecules that are
rationally designed to accumulate
in diseased cells and disrupt
energy metabolism. Its lead
texaphyrin-based product
candidates are Xcytrin motexafin
gadolinium, a molecule to treat
cancer by increasing tumor
responsiveness to radiation and
chemotherapy, and Antrin
motexafin lutetium, a molecule to
treat atherosclerosis via
phototherapy. |
| Financial Info: |
For the
nine months ended 3/31/03,
Company reports no revenues for
both periods. Net loss fell 29%
to $20.8 million. |
| |
|
| Key Ratios: |
Current
Ratio: 43.70; Total Debt/Equity:
0, P/E: N/A, Price/Book: 0.80,
Price/Sales: N/A |
| |
|
| Share Info: |
There are 16.2
million shares outstanding with
15.4 million shares in the
trading float. 87 institutions own
approximately 57% of the shares
outstanding. There have been 3
insiders buying a total of 2,000
shares in the last six months.
As of 6/9/2003, there were 578,000
shares short.
Net Institutional Selling: 163,000
shares: prior to latest quarter. |
| |
|
| Articles: |
Pharmacyclics
Announces Publication of Phase 3
Study of Xcytrin For Brain
Metastases |
|
